Market Overview

The Only Bullish Scenario For Juno Therapeutics: Its CEO May Get Fired

The Only Bullish Scenario For Juno Therapeutics: Its CEO May Get Fired
Related JUNO
An Eventful February Took Its Toll On TD Ameritrade's Investor Index
Investor Movement Index February Summary
Related NVS
Biotech Winners And Losers From Congress' Latest Funding Bill
Regulatory Concern For Celgene's Ozanimod Could Be Big For Arena Pharma, Novartis
Surface Oncology on deck for IPO (Seeking Alpha)

As Juno Therapeutics Inc (NASDAQ: JUNO) continues to trail its peers, BTIG analyst Dane Leone sees the stock falling nearly 50 percent as he downgrades his rating to Sell and set a price target of $12 (see Dane Leone's track record).

“The company is trailing peers [Kite Pharma Inc (NASDAQ: KITE) and Novartis AG (ADR) (NYSE: NVS)] to market, and we still do not have demonstrative proof that JUNO products will be differentiated on efficacy or toxicity. Overall, our market model for JCAR017 is ~$1bn below consensus sales expectations out to 2026E as we are not sure that the company will be competitive in DLBCL,” Leone said.

3 Key Takeaways

    1. The data for Transcend does not support outpatient use, and Leone pointed out that with its high toxicity, it does seem like Juno has a “decentralized delivery model.” Overall, there is a lot of uncertainty around the Juno Therapeutics dataset.
    2. Juno is already entering a very competitive field with its early-stage clinical pipeline additions including an anti-BCMA CAR T. Some of the players in this industry include Kite Pharma and bluebird bio Inc (NASDAQ: BLUE).
    3. Due to Juno’s strategic errors, Leone highlighted the possibility that CEO Hans Bishop is removed this year. Leone actually believes this could be a positive for Juno as the company has potential if managed correctly.

Leone concluded by saying: “Overall the ‘defined cell population strategy’ is a complete show-me story, as data to date has not been convincing, and we think the retrenched strategy post the ROCKET failure has pushed the competitive timelines so far behind peers within the CD19+ race that the company will ultimately be reliant on earlier stage products – for which we have very little data.”

Juno Therapeutics was trading down over 5 percent during Thursday’s pre-market trading session, but quickly lost those gains following the opening bell. At last check, shares of Juno were down 4.34 percent at $22.70.

Related Links:

Attention Bluebird Bio Investors: Analyst Sees Upside Following Strong Therapy Results

Key Reasons BTIG Just Upgraded Kite Pharma

Latest Ratings for JUNO

Jan 2018Standpoint ResearchDowngradesBuyHold
Jan 2018BarclaysDowngradesOverweightEqual-Weight
Jan 2018Maxim GroupDowngradesBuyHold

View More Analyst Ratings for JUNO
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Downgrades Rumors Price Target Management Analyst Ratings Best of Benzinga


Related Articles (BLUE + JUNO)

View Comments and Join the Discussion!